Elevance Health, Inc. (ELV) Form 10-Q — Oct 21, 2026
Elevance Health reported Q3 2026 diluted EPS of $6.27, up 17.9% from $5.32 a year ago, on operating revenue of $50.44 billion and net investment income that jumped 65.9% to $1.04 billion. The year-to-date picture is weaker: nine-month shareholders' net income fell 10.2% to $4.59 billion and EPS dropped 7.3% to $21.01, driven by a $935 million CMS risk-adjustment data accrual, elevated Medicaid medical costs, and a 20.3% decline in Health Benefits operating gain. Medical membership slipped 1.1% to 44.9 million, with Medicare Advantage down 15.5% on deliberate repositioning.
Key figures
- Eps
- 6.27
- Revenue
- 152084000000
- Net Income
- 1365000000
- Total Assets
- 127801000000
- Cash Position
- 10348000000
- Shares Outstanding
- 216055891
- Cms paid usd m
- 342
- Nine month eps
- 21.01
- Q3 eps change pct
- 17.9
- Q3 eps prior year
- 5.32
- Cms loss range usd m
- +/-320
- Q3 operating gain usd m
- 1269
- Cms accrual balance usd m
- 593
- Buybacks nine months usd m
- 1688
- Cms accrual original usd m
- 935
- Q3 operating revenue usd m
- 50440
- Q3 operating gain change pct
- -2
- Net investment income q3 usd m
- 1037
- Nine month operating gain usd m
- 5118
- Operating cash flow nine months usd m
- 7512
- Nine month shareholders net income usd m
- 4592
- Ma members in 4plus star plans pct 2026 ratings
- 55
- Ma members in 4plus star plans pct 2027 ratings
- 49
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.